fig3

Figure 3. Predictive survival ability combining PLR-NLR information: (A) diagram boxes comparing median survival after BVZ administration among the three groups; (B) overall survival from BVZ administration calculated by Kaplan-Meier curves for 31 patients stratified into three groups, namely double positive, double negative, and single positive; (C) overall survival from BVZ administration calculated by Kaplan-Meier curves for 31 patients stratified into a double-positive group and otherwise. BVZ: bevacizumab; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio